Selecting a contract research organization (CRO) is one of the highest-stakes decisions a sponsor makes during drug or device development. The right partner accelerates timelines, protects data integrity, and keeps costs predictable. The wrong one creates delays that compound across every downstream milestone.
Yet many sponsors still evaluate CRO performance through retrospective reviews or anecdotal feedback. A more effective approach is to define and track a small set of leading indicators from the start—metrics that reveal whether a study is on course before problems become costly.
Here are five metrics that consistently predict CRO success, along with practical guidance on measuring each.
Site activation cycle time measures the number of business days between regulatory or ethics submission and a site being cleared to enroll its first patient. It captures the efficiency of study start-up activities, including contract execution, IRB/ethics approval, and site initiation.
Why it matters: Approximately 80% of clinical trials fail to meet their initial enrollment timelines, and delays during start-up are a primary contributor. Every additional week a site sits inactive is a week of lost enrollment opportunity, compressing downstream timelines.
How to measure it: Track business days from submission to the date the site is activated in your Clinical Trial Management System (CTMS). Set thresholds based on study complexity. For example, a target of 10 business days or fewer from the site initiation visit (SIV) to activation is a strong benchmark for domestic studies, while 15 or more business days may signal bottlenecks.
What to watch for: Regional variation is normal, but persistent delays at specific sites or within specific regulatory environments should trigger a rootcause review with your CRO partner.
This metric compares actual patient enrollment against the projected enrollment curve agreed upon at study outset. It is the single most visible indicator of whether a study will finish on time.
Why it matters: Enrollment delays are the most common driver of clinical trial cost overruns. Industry data shows that trial recruitment durations have increased significantly over the past decade, with Phase III recruitment timelines rising from approximately 13 months to 18 months between 2008 and 2019. For sponsors, each month of delay can translate to significant revenue loss, particularly for products approaching patent expiration or competitive market windows.
How to measure it: Plot cumulative enrollment against the forecast curve monthly. Calculate the enrollment variance as a percentage: (Actual Enrolled / Forecasted Enrolled) × 100. A sustained variance below 80% should prompt a formal mitigation discussion covering site-level performance, screen failure rates, and recruitment strategy adjustments.
What to watch for: Look beyond aggregate numbers. A study can appear on track overall while individual sites are significantly underperforming. Site-level enrollment tracking helps identify where targeted intervention is needed.
Query resolution time tracks how long open data queries remain unresolved in the electronic data capture (EDC) system. Specifically, the percentage of open queries aging beyond 30 days is a strong proxy for data management responsiveness and site engagement.
Why it matters: Unresolved queries erode data quality, delay database lock, and create compliance risk during regulatory inspections. The FDA has noted a 12% increase in clinical holds related to data integrity concerns in recent years, underscoring the importance of clean, timely data.
How to measure it: Export your open query report from the EDC system. Calculate the percentage of queries open longer than 30 days: (Queries Open > 30 Days / Total Open Queries) × 100. A threshold below 20% indicates strong performance. Between 20% and 30% warrants attention, and above 31% signals a systemic issue requiring corrective action.
What to watch for: A high percentage of aged queries often points to CRA follow-up gaps, inadequate site training on the EDC, or insufficient data management oversight. Address the root cause rather than just the number.
This metric measures the percentage of monitoring visit reports finalized and approved within the timeframe defined in the Clinical Monitoring Plan (CMP). It reflects the CRO’s discipline around documentation and the clinical team’s operational cadence.
Why it matters: Late monitoring reports delay issue identification, slow corrective action, and create gaps in the audit trail. Consistent, on-time reporting is also a direct indicator of CRA workload balance. When turnaround times slip, it often signals that CRAs are stretched across too many sites or studies.
How to measure it: Track the average turnaround in business days from the monitoring visit date to report approval. A target of 98% or higher on-time delivery is achievable for well-resourced studies. Rates between 85% and 97% are acceptable but should be monitored, and anything below 84% should be escalated.
What to watch for: Turnaround times that deteriorate over the life of a study frequently indicate resource strain. This is an early warning metric—address it before it compounds into monitoring backlogs and data quality issues.
Patient retention rate measures the percentage of enrolled subjects who complete the study through the final protocol-defined visit. It is the bookend to enrollment and a critical determinant of whether the study produces sufficient data for a robust analysis.
Why it matters: Industry data indicate that approximately 30% of clinical trial participants drop out after enrollment, with 17% abandoning trials prematurely. High dropout rates jeopardize statistical power, can require protocol amendments to increase sample size, and add cost and time to an already constrained program.
How to measure it: Calculate retention as: (Subjects Completing Final Visit / Total Subjects Enrolled) × 100. Monitor trends by site and by visit interval. A sudden increase in dropouts within a specific visit window may indicate protocol burden, concerns about adverse events, or site-level engagement issues.
What to watch for: Retention is influenced by protocol design, patient burden, and site-level support. A CRO that proactively tracks retention trends and implements targeted interventions—patient engagement programs, visit scheduling flexibility, travel support—is demonstrating the kind of operational maturity that predicts long-term study success.
These five metrics provide a quantitative framework for evaluating CRO performance, but they work best when combined with qualitative oversight. Numbers tell you what is happening. Culture, communication, and leadership tell you why.
A CRO that delivers strong metrics while maintaining transparency, proactively communicating risks, and demonstrating a commitment to continuous improvement is a partner positioned to execute reliably across the full study lifecycle.
At ProPharma, our Clinical Research Solutions team integrates structured metric tracking with the operational discipline and team culture needed to deliver consistent results. From study start-up through close-out, we partner with sponsors to maintain visibility, manage risk, and protect the integrity of every milestone.
Learn more about how our Clinical Research Solutions team supports reliable clinical execution at every stage of development or contact us today.